N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene–environment interaction by Green, J et al.
Genetically based variability (polymorphism) in the activity of
carcinogen metabolizing enzymes may influence susceptibility to
environmental carcinogens (Vineis et al, 1999). The major risk
factors for bladder cancer are cigarette smoking, which is associ-
ated with a 2 to 8-fold increase in risk and may account for
50–60% of cases, and occupational exposure to arylamines such as
2-naphthylamine, 4-aminobiphenyl and benzidine, associated with
an increased risk of up to 160-fold and a factor in perhaps 10–20%
of cases (Hein, 1988; Silverman et al, 1996; Grant et al, 1997).
Cigarette smoke contains arylamines, including 2-naphthylamine
and 4-aminobiphenyl, which could explain its effects in inducing
bladder cancer (Vineis, 1992; Peluso et al, 1998; Sorlie et al,
1998). There is no evidence for an appreciable role of high-
penetrance genes in determining bladder-cancer risk (Cartwright,
1979; Kantor et al, 1985; Kiemeny et al, 1997).
The carcinogen-metabolizing enzyme N-acetyltransferase
2 (NAT2) is important in the inactivation of arylamines. There are
two distinct phenotypes for NAT2: ‘fast’ and ‘slow’ acetylators,
measured in vivo using substrates such as isoniazid, dapsone and
caffeine. The slow form of NAT2 is present in up to 90% of some
Arab populations, in 40–60% of Caucasians, including Indians,
and in 5–25% of East Asians (Lin et al, 1994; Woolhouse et al,
1997; Xie et al, 1997). It has been suggested that slow acteylators
may be at increased risk of bladder cancer when exposed to envi-
ronmental arylamine carcinogens, due to their slower inactivation.
Some but not all published case-control studies have provided
support for this hypothesis (d’Errico et al, 1996; 1999).
The aims of this paper are first, to assess the evidence from
published case-control studies for an association between the
NAT2 slow phenotype or genotype and bladder cancer risk; and
secondly, to consider whether existing evidence supports the
hypothesis that the effect of the NAT2 polymorphism on bladder
cancer risk will be seen primarily in those exposed to tobacco
smoke or to occupational arylamine carcinogens.
METHODS
Case-control studies of the NAT2 polymorphism and bladder
cancer published up to the end of 1998 were identified through
searches of Medline and Embase databases, supplemented by
searches of references given in identified papers and by hand
searches of relevant journals. No restriction was placed on the
language of publication. No attempt was made to identify unpub-
lished studies or unpublished data from published studies.
Analyses were restricted to studies with at least 50 cases and with
adequate information on exposure and outcome measures.
Unadjusted odds ratios (with 95% confidence intervals) for
bladder cancer in NAT2 slow acetylators compared with NAT2
fast acetylators were calculated for each study using published
figures. NAT2 slow and fast acetylators were as defined in each
study according to the published methods for phenotyping or
genotyping. Odds ratios were compared between groups of studies
based on type of control group, method used to determine acetyla-
tion status (phenotype or genotype), and ethnic group (Caucasian
(Europe, USA, India) or East Asian (Japan, Korea, Taiwan), based
on ethnic origin of subjects, where given, or country where study
was performed). In studies with sufficient information, odds ratios
were calculated separately for smokers and for non-smokers
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and for those not occupationally exposed. The relationship
between smoking per se and NAT2 status in the study populations
was evaluated by calculating the odds ratio for smoking in NAT2
slow compared with NAT2 fast acetylators in the controls from the
five studies providing sufficient information. Summary odds ratios
were calculated by the Mantel–Haenszel method. The method of
empirically weighted least squares was used to test for hetero-
geneity within and between the odds ratios for each of the groups
or subgroups of studies (Cox and Snell, 1989).
The evidence for the associations investigated in this paper has
been summarized graphically in Figures 1 to 3. In Figures 1 and 3,
studies are listed in order of study size (number of cases), from
largest to smallest. In Figure 2, studies are listed in order of date of
publication, earliest first, within each group. In these Figures,
black squares indicate odds ratios, the area of each square being
proportional to the amount of statistical information contributed,
with horizontal lines indicating 95% confidence intervals. Vertical
dashed lines represent point estimates of summary odds ratios.
Confidence intervals for summary odds ratios were calculated but
have not been included in the Figures because we believe that they
may underestimate substantially the degree of uncertainty in the
results due to publication bias and to limitations in the design of
studies.
RESULTS
In total, 27 published studies were identified. Of these, 21 met the
eligibility criteria (Lower et al, 1979 (two studies); Cartwright et
al, 1982; Evans et al, 1983; Hanssen et al, 1985; Ladero et al,
1985; Mommsen et al, 1985; Sone, 1986; Kaisary et al, 1987;
Horai et al, 1989; Roots et al, 1989; Hanke and Krajewska, 1990;
Lee et al, 1994; Dewan et al, 1995; Ishizu et al, 1995; Risch et al,
1995; Brockmöller et al, 1996; Okkels et al, 1997; Peluso et al,
1998; Su et al, 1998; Taylor et al, 1998). Of the remaining six
studies, five had fewer than 50 cases (Woodhouse et al, 1982;
Miller and Cosgriff, 1983; Karakaya et al, 1986; Bicho et al, 1988;
Hayes et al, 1993) and one gave insufficient information on
methods and results to allow calculation of odds ratios (Probert
et al, 1998). These studies were not included in the analysis.
The 21 studies included in the analysis varied considerably in
size and in design and most did not provide sufficient information
to allow a full assessment of the relationship between the NAT2
polymorphism and smoking or occupational exposure in relation
to bladder cancer risk. For example, 2/21 studies gave response
rates and 12/21 studies stated whether cases were incident or
prevalent. Five studies provided information on smoking for both
cases and controls in sufficient detail to allow the calculation of
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odds ratios for bladder cancer risk in NAT2 slow vs fast acetylators
stratified by smoking (Dewan et al, 1995; Ishizu et al, 1995; Risch
et al, 1995; Brockmöller et al, 1996; Taylor et al, 1998). Smoking
was also measured for cases and controls in the study by Okkels et
al (1997) but published figures were insufficient to allow stratified
analysis comparable with the other studies. In a further five studies
smoking data were given only for cases (Cartwright
et al, 1982; Hanssen et al, 1985; Horai et al, 1989; Ladero et al,
1985, all of which included both smokers and non-smokers among
cases; Evans et al, 1983, in which all cases were smokers). It is not
possible to calculate comparable odds ratios of the risk of bladder
cancer for NAT2 slow vs fast separately for smokers and non-
smokers in these studies. We did not consider that a case-only
analysis of the potential interaction between NAT2 and smoking
would be justified; this would depend crucially on independence
between NAT2 acetylation status and smoking status, which has
not been fully established.
Information on occupational exposure to arylamines was given
for both cases and controls in four studies (Sone, 1986; Kaisary
et al, 1987; Lee et al, 1994; Brockmöller et al, 1996); in two of
these, none of the subjects was occupationally exposed (Kaisary
et al, 1987; Lee et al, 1994). Six studies included both occupation-
ally exposed and non-occupationally exposed cases, but gave no
information on occupational exposure for controls and therefore
could not be included in the analyses (Cartwright et al, 1982;
Evans et al, 1983; Hanssen et al, 1985; Ladero et al, 1985; Hanke
and Krajewska, 1990; Risch et al, 1995). Definitions of smoking
and occupational exposure varied widely between studies.
Figure 1 shows the odds ratios for bladder cancer in NAT2 slow
acetylators compared with NAT2 fast acetylators in the 21 eligible
studies. Estimates ranged from 0.57–2.82, with four studies
showing a statistically significant positive association between
NAT2 slow and risk of bladder cancer. There was no significant
statistical heterogeneity between studies overall (c2
20 = 25.90,
P = 0.16), and no significant heterogeneity within or between
groups of studies based on type of control group (hospital urology,
hospital general, population or mixed hospital and population
controls; between groups c2
3 = 2.80, P = 0.43), method used to
determine acetylation status (phenotype or genotype; between
groups c2
1 = 2.33, P = 0.13, studies indicated on Figure 1) or
ethnic group (East Asian compared with Caucasian; between
groups  c2
1 = 0.07, P = 0.79, Figure 2). The point estimate of the
summary odds ratio for all 21 studies was 1.41, based on a total of
2700 cases and 3426 controls. The 95% confidence limits for this
estimate were 1.26–1.59, but are of questionable value given the
limitations outlined in the Discussion.
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Smoking
Smoking and the NAT2 polymorphism in people without
bladder cancer
In no study was there a significant association between the NAT2
polymorphism and smoking status and there was no significant
heterogeneity between studies (p = 0.77). The summary odds ratio
for smoking in NAT2 slow vs NAT2 fast acetylators in controls
from five studies was 0.79 (0.56–1.11), based on a total of 541
smokers and 245 non-smokers.
Relationship between the NAT2 polymorphism and bladder
cancer in smokers compared with non-smokers
Figure 3 shows the odds ratios for bladder cancer in NAT2 slow vs
NAT2 fast acetylators in smokers and in non-smokers in the five
studies with this information. In no individual study was there a
significant difference at the 5% level between the odds ratio in
smokers and that in non-smokers. There was significant hetero-
geneity between studies in the smoking subgroup (p = 0.02). Point
estimates of summary odds ratios were 1.59 for smokers (689
cases and 541 controls) and 1.02 for non-smokers (217 cases and
245 controls). In view of the heterogeneity of results in smokers,
no statistical comparison of the summary odds ratios for bladder
cancer in NAT2 slow vs NAT2 fast acetylators in smokers and
non-smokers was attempted.
Interaction between genetic and environmental risk factors may
also be evaluated by means of an ‘odds ratio for interaction’
(Hwang et al, 1994) or ‘interaction odds ratio’ (Cuzick, 1999),
defined as:
odds ratio for bladder cancer in NAT2 slow vs fast acetylators
in smokers/odds ratio for bladder cancer in NAT2 slow vs fast
acetylators in non-smokers
and providing a direct comparison between the effects of NAT2 in
smokers and in non-smokers within each study. In view of the
unreliability of individual study estimates and the possibility of
publication bias this calculation was not performed.
Occupational exposure
Occupational exposure and the NAT2 polymorphism in
people without bladder cancer
The relationship between the NAT2 polymorphism and whether or
not individuals were occupationally exposed to arylamines was
evaluated in controls from the only study providing the necessary
information (Brockmöller et al, 1996). The odds ratio for occupa-
tional exposure in slow compared with fast acetylators was 0.74
(0.43–1.26), based on 77 occupationally exposed and 296
non-occupationally exposed subjects.
Relationship between the NAT2 polymorphism and bladder
cancer in occupationally exposed subjects compared with
non-occupationally exposed subjects
Odds ratios for bladder cancer for NAT2 slow vs NAT2 fast acety-
lators in occupationally exposed and non-occupationally exposed
subjects were calculated for the two studies with sufficient infor-
mation on exposure and outcome. Sone (1986) found odds ratios
of 0.52 (0.07–2.96) in occupationally exposed subjects and 1.85
(0.15–48.69) in non-occupationally exposed subjects; for
Brockmöller et al (1996) odds ratios were 1.55 (0.85–2.83) in
occupationally exposed and 1.16 (0.80–1.67) in non-occupation-
ally exposed subjects. In neither study were the odds ratios for
exposed and non-exposed subjects significantly different from
each other. These studies differed in their definition of
occupational exposure and no combined analysis was attempted.
DISCUSSION
Interest in the possible role of the NAT2 polymorphism in deter-
mining susceptibility to bladder cancer followed identification of
industrial arylamines as potent bladder carcinogens (Case et al,
1954), and recognition of the role of N-acetyltransferases in
arylamine metabolism (Hein, 1988). Involvement of NAT2 in
smoking-related bladder cancer was suggested by identification of
arylamines in cigarette smoke and has been supported by studies
on haemoglobin- and DNA-adducts (Vineis, 1992) and by recent
work on somatic mutation patterns in bladder cancers (Sorlie et al,
1998). Early case-control studies reported a strong association
between the NAT2 slow phenotype and bladder cancer in subjects
occupationally exposed to arylamines, with odds ratios for bladder
cancer in NAT2 slow vs fast acetylators as high as 16.7
(Cartwright et al, 1982; Ladero et al, 1985; Hanke and Krajewska,
1990). In all of these early studies occupationally exposed subjects
were compared with controls whose occupational exposure status
was not known. Subsequent studies with varying extents and types
of environmental exposure have produced inconsistent results.
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Few studies, however, have explicitly tested the hypothesis of
interaction between NAT2 and smoking or occupational exposure
in relation to bladder-cancer risk, although this is one of the best
theoretical examples available of possible gene–environment
interaction. To test for the effects of specific genetic and environ-
mental risk factors, and to examine any possible statistical interac-
tion between them, both types of exposure need to be measured
accurately in cases and in controls. Only five of the studies
discussed here gave adequate information on smoking for cases
and controls, and occupational exposure was measured in cases
and controls in only two studies. None of these studies was
designed in such a way that the individual effects on bladder-
cancer risk of the NAT2 polymorphism and of the environmental
exposure could both be measured. The majority of studies thus
provide only an overall measure of the effect of NAT2 on bladder-
cancer risk, and the lack of information about environmental
exposure makes these estimates difficult to compare.
Interpretation of the results of the 21 case-control studies
reviewed here is limited also by the unreliability of individual
study results and by possible selective publication of positive
results (publication bias). The majority of studies gave inadequate
information on case and control selection. Case definition was
generally poor and in many studies no histological confirmation of
diagnosis was required; sub-types of cancer, including the two
common types of superficial transitional cell carcinoma of the
bladder, may vary in their genetic and environmental aetiologies
(Knowles, 1998; Le Marchand et al, 1998; Whiteman et al, 1998).
The selective publication of studies (in particular small studies)
with positive results is common and means that the validity of any
summary measure is open to question (Egger et al, 1998). There is
some evidence to suggest such publication bias among the studies
reviewed here (Figures 1 and 3), with the odds ratios for bladder
cancer in NAT2 slow vs NAT2 fast acetylators being higher in the
smaller studies, especially among smokers.
Bearing in mind these difficulties in interpretation, it is possible
to draw some useful conclusions from the data reviewed here.
First, compared with the substantial risks of bladder cancer associ-
ated with smoking and occupational exposure to arylamines, the
effect of acetylation status on an individual’s risk of developing
bladder cancer, if there is any effect at all, is likely to be small. The
overall summary risk estimate suggests an increase in risk of about
40% associated with the NAT2 slow phenotype or genotype. Any
gene–environment interaction also seems likely to be small;
although the summary odds ratio for bladder cancer associated
with NAT2 slow was estimated at 1.6 in smokers and 1.0 in non-
smokers, it should be noted that this difference may have been
exaggerated by publication bias. Secondly, we found no significant
difference in the effect of NAT2 on bladder-cancer risk between
studies in Caucasian (European, Indian and North American) and
those in East Asian (Chinese, Japanese and Korean) populations,
or between studies based on phenotype and studies based on geno-
type. In two previous meta-analyses, d’Errico et al (1996; 1999)
found an association between NAT2 slow and bladder-cancer risk
only in Caucasians. They, however, had fewer East Asian studies
available, and indeed in the present analysis the few East Asian
studies were too small to allow an accurate estimation of the effect
of NAT2 slow in East Asian populations. Agreement between
phenotype and genotype studies is not surprising; NAT2 is not
inducible by its substrates, and the NAT2 polymorphism is very
well characterized with excellent genotype–phenotype correlation
(Smith et al, 1997; Hirvonen, 1999). At least nine different
mutated (‘slow’) alleles, resulting from combinations of at least
seven different base-pair substitutions (mutations) have been iden-
tified for NAT2 (Vatsis et al, 1995; Hirvonen, 1999), and different
slow alleles may be associated with differences in acetylation rate
(Cascorbi et al, 1995).
If the effect of NAT2 on bladder-cancer risk is of the size
suggested by these summary figures, full examination of the effect
within particular exposure groups, for example smokers and non-
smokers, will require studies with very large numbers. At least 600
cases and 600 controls would be needed to detect an overall odds
ratio (ignoring the effect of environmental exposure) for the effect
of NAT2 slow vs NAT2 fast of 1.4 with 80% power and 5%
significance, nearly twice the size of the largest available
published study. In order to detect a difference of 1.6-fold in the
effect on bladder cancer risk of NAT2 slow vs NAT2 fast in
smokers compared with non-smokers (assuming no effect of
NAT2 in non-smokers, an odds ratio of 3 for the effect of smoking
on bladder-cancer risk, a prevalence of NAT2 slow acetylator
status in controls of 0.5 and prevalence of smoking in cases and
controls of 0.5), an unmatched case-control study would require at
least 3000 cases and 3000 controls. The sample size is very sensi-
tive to small changes in parameter; for example, to detect a differ-
ence in the effect of NAT2 between smokers and non-smokers of
1.5-fold (rather than 1.6-fold) would require at least 5000 cases
and 5000 controls. The required study size would need to be
further increased to allow for adjustment for confounding, for the
effects of misclassification of gene or exposure status (Rothman et
al, 1999), for modelling the results by levels of exposure and/or for
possible interactions with other gene polymorphisms (e.g. N-
acetyltransferase 1 (NAT1); Hirvonen, 1999) or with other envi-
ronmental exposures. Although desirable, studies dealing with
several different risk factors and possible interactions between
them need to be interpreted cautiously in order to avoid the danger
of over-emphasizing statistically significant results in small sub-
groups (Oxman and Guyatt, 1992; Cuzick, 1999).
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